BioNTech and OncoC4 reported Phase 3 survival data for their anti‑CTLA‑4 candidate that showed a large reduction in death risk in lung cancer, but subsequent analysis highlighted a challenging tolerability profile that could constrain adoption. Company releases and trial documents indicated survival benefit, while independent review flagged higher rates of immune‑related adverse events. Analysts noted the survival signal is clinically meaningful but warned that severe toxicities typical of CTLA‑4 blockade will require careful management and could limit eligible patient populations. BioNTech and OncoC4 plan to balance regulatory positioning with risk‑mitigation strategies and detailed safety labeling. The data revive interest in CTLA‑4 platforms but underscore the tradeoff between potency and tolerability for checkpoint therapies in solid tumors.